Alexion sags after Soliris' myasthenia gravis miss

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) sank $16.86 (11%) to $138.13 on Tuesday after post-market news Monday that Soliris eculizumab missed the primary endpoint in the Phase III REGAIN study to treat refractory generalized myasthenia gravis. On a conference call Monday, CEO David Hallal said the "totality of the clinical data" support Soliris' efficacy in the indication, and Alexion plans to meet with regulators to discuss next steps (see BioCentury Extra, June 6). ...